Juan Li1, Huiyan Xu, Qian Gao, Yanting Wen. 1. Department of Hematology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.
Abstract
PURPOSE: Current evidence suggests that erythropoiesis-stimulating agents (ESAs), including erythropoietin and darbepoetin, may have a direct cardio-protective effect. However, randomized controlled trials (RCTs) assessing the efficacy and safety of ESAs in patients with acute ST-segment elevation myocardial infarction (STEMI) have yielded heterogeneous results. Here, we performed a meta-analysis of RCTs to assess whether the administration of ESAs can improve cardiac functional parameters, such as left ventricular ejection fraction (LVEF), left ventricular end-systolic volume (LVESV), and left ventricular end-diastolic volume (LVEDV), and attenuate infarct size in patients with acute STEMI. METHODS AND RESULTS: The PubMed, EBSCO, EMBASE, and Cochrane Central Register of Controlled Trials databases were searched for relevant RCT studies on ESAs published before May 13, 2011. A total of nine RCTs involving 1,244 participants were identified. The original data of these studies were aggregated using fixed effect models. Compared with controls, the administration of ESAs showed a slight but significant improvement in LVEF (1.38%; 95% confidence interval 0.38-2.37%; p = 0.007). However, no significant improvement in LVEDV, LVESV, and infarct size was observed, and no increase in all-cause severe adverse effect was indicated. CONCLUSIONS: Our meta-analysis indicates that the superiority of ESAs over conventional therapy in patients with acute STEMI is limited using current procedures. However, there is evidence to suggest that the timing and dosing of ESA administration may be optimized. Moreover, the long-term cardio-protective effect of ESAs in this patient population may be beneficial and worth exploring.
PURPOSE: Current evidence suggests that erythropoiesis-stimulating agents (ESAs), including erythropoietin and darbepoetin, may have a direct cardio-protective effect. However, randomized controlled trials (RCTs) assessing the efficacy and safety of ESAs in patients with acute ST-segment elevation myocardial infarction (STEMI) have yielded heterogeneous results. Here, we performed a meta-analysis of RCTs to assess whether the administration of ESAs can improve cardiac functional parameters, such as left ventricular ejection fraction (LVEF), left ventricular end-systolic volume (LVESV), and left ventricular end-diastolic volume (LVEDV), and attenuate infarct size in patients with acute STEMI. METHODS AND RESULTS: The PubMed, EBSCO, EMBASE, and Cochrane Central Register of Controlled Trials databases were searched for relevant RCT studies on ESAs published before May 13, 2011. A total of nine RCTs involving 1,244 participants were identified. The original data of these studies were aggregated using fixed effect models. Compared with controls, the administration of ESAs showed a slight but significant improvement in LVEF (1.38%; 95% confidence interval 0.38-2.37%; p = 0.007). However, no significant improvement in LVEDV, LVESV, and infarct size was observed, and no increase in all-cause severe adverse effect was indicated. CONCLUSIONS: Our meta-analysis indicates that the superiority of ESAs over conventional therapy in patients with acute STEMI is limited using current procedures. However, there is evidence to suggest that the timing and dosing of ESA administration may be optimized. Moreover, the long-term cardio-protective effect of ESAs in this patient population may be beneficial and worth exploring.
Authors: R S Syed; S W Reid; C Li; J C Cheetham; K H Aoki; B Liu; H Zhan; T D Osslund; A J Chirino; J Zhang; J Finer-Moore; S Elliott; K Sitney; B A Katz; D J Matthews; J J Wendoloski; J Egrie; R M Stroud Journal: Nature Date: 1998-10-01 Impact factor: 49.962
Authors: Christopher Heeschen; Alexandra Aicher; Ralf Lehmann; Stephan Fichtlscherer; Mariuca Vasa; Carmen Urbich; Christiane Mildner-Rihm; Hans Martin; Andreas M Zeiher; Stefanie Dimmeler Journal: Blood Date: 2003-04-17 Impact factor: 22.113
Authors: Erik Lipsic; Peter van der Meer; Adriaan A Voors; B Daan Westenbrink; Ad F M van den Heuvel; Hetty C de Boer; Anton J van Zonneveld; Regien G Schoemaker; Wiek H van Gilst; Felix Zijlstra; Dirk J van Veldhuisen Journal: Cardiovasc Drugs Ther Date: 2006-04 Impact factor: 3.727
Authors: Donna M Mancini; Stuart D Katz; Chim C Lang; John LaManca; Alhakam Hudaihed; Ana-Silvia Androne Journal: Circulation Date: 2003-01-21 Impact factor: 29.690
Authors: Erik Lipsic; Peter van der Meer; Robert H Henning; Albert J H Suurmeijer; Kristien M Boddeus; Dirk J van Veldhuisen; Wiek H van Gilst; Regien G Schoemaker Journal: J Cardiovasc Pharmacol Date: 2004-10 Impact factor: 3.105
Authors: Jalal K Ghali; Inder S Anand; William T Abraham; Gregg C Fonarow; Barry Greenberg; Henry Krum; Barry M Massie; Scott M Wasserman; Marie-Louise Trotman; Yan Sun; Beat Knusel; Paul Armstrong Journal: Circulation Date: 2008-01-14 Impact factor: 29.690